PLASMA COENZYME Q10 LEVELS OF INDIVIDUALS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND DIABETES INDIVIDUALS WITH ADVANCED MICROALBUMINURIA: A COMPARATIVE STUDY.

Objective: Diabetes is a chronic disease that causes the development of microalbuminuria. CoQlO deficiency is common in people with type 2 diabetes. This study aims to evaluate whether coenzyme Q10 (CoQlO) levels are a risk factor for diabetes and microalbuminuria in newly diagnosed diabetes and advanced microalbuminuria. Material and Method: The study was conducted with patients who came to the internal medicine outpatient clinic. Plasma CoQlO and malondialdehyde (MDA) values of 90 people in total, including 30 people in each group, newly diagnosed Type 2 diabetes (Group D), diabetes mellitus with microalbuminuria (Group M), and the control group (Group C) were examined. Results: There was no difference between plasma CoQlO and MDA levels of newly diagnosed type 2 diabetes patients and those with microalbuminuria (p>0.05). There was a negative correlation between CoQlO and fasting glucose and HbAlc in all groups (p<0.05). A positive correlation was observed between CoQlO and MDA (p<0.05). CoQlO level of the control group was found to be higher than Group D and M (p<0.05); the difference between Group M and Group D was not significant (p>0.05). As a result of regression analysis, increasing the CoQlO value was found to have a protective effect on the risk of diabetes (95 %CI: p=0.005). Conclusion: This study showed that individuals with low blood sugar and HbAlc had high CoQlO levels. We think that CoQlO can be considered a risk factor for diabetes, and further studies examining total CoQlO and ubiquinol/ubiquinone ratio would be beneficial. [ABSTRACT FROM AUTHOR]